What Are the Best Treatment Options for Vulvar Lichen Sclerosus?

Genital lichen sclerosus—commonly referred to colloquially as “vulvar white patches”—is a chronic, inflammatory dermatosis that primarily affects the anogenital skin. It is characterized by ivory-white, parchment-like plaques, often accompanied by intense pruritus, pain, dyspareunia, and, in advanced cases, architectural distortion such as labial fusion or introital narrowing.

While the exact etiology remains incompletely understood, current evidence points to a multifactorial pathogenesis involving autoimmune dysregulation, genetic predisposition, hormonal influences (particularly low estrogen states), and possible environmental triggers. Importantly, untreated or poorly controlled disease carries a small but well-documented increased risk of squamous cell carcinoma—estimated at 3–5% over decades—underscoring the necessity of long-term monitoring and proactive management.

First-line therapy remains high-potency topical corticosteroids, most notably clobetasol propionate 0.05% ointment. Initiated at daily application for 6–12 weeks, treatment is then carefully tapered to maintenance dosing—typically twice weekly—to sustain remission and minimize adverse effects such as epidermal atrophy. Patient education on proper application technique, avoidance of irritants (e.g., scented soaps, tight synthetic fabrics), and consistent follow-up every 6–12 months is integral to successful outcomes.

For patients with refractory symptoms or steroid intolerance, second-line options include topical calcineurin inhibitors (e.g., tacrolimus 0.1% ointment) and, in select cases, intralesional corticosteroid injections or phototherapy. Emerging data support the adjunctive use of vaginal estrogen therapy in postmenopausal individuals to improve tissue elasticity and barrier function—though systemic hormone therapy is not indicated solely for lichen sclerosus.

Surgical intervention is rarely indicated and reserved exclusively for complications such as severe stenosis or biopsy-confirmed malignancy. Regular clinical examination—including visual inspection and targeted biopsy of any non-healing, ulcerated, or indurated lesions—is essential for early detection of malignant transformation.